Evaluation of diagnostic tests when there is no gold standard. A review of methodsAnne WS Rutjes, Peter Bossuyt, Johannes B. Reitsma et al.|Health Technology Assessment|2007Cited by 526
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D’Haens, Marc Ferrante, Julián Panés et al.|The Lancet|2022Cited by 383
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic ResectionMiguel Regueiro, Pierre Desreumaux, Brian G. Feagan et al.|Gastroenterology|2016Cited by 329
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Geert D’Haens, Remo Panaccione et al.|The Lancet|2022Cited by 312
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE studyAnnick Moens, Marc Ferrante, C. Janneke van der Woude et al.|Alimentary Pharmacology & Therapeutics|2019Cited by 137